Drug Enforcement Administration December 17, 2015 – Federal Register Recent Federal Regulation Documents
Results 1 - 5 of 5
Schedules of Controlled Substances: Placement of Eluxadoline Into Schedule IV; Correction
The Drug Enforcement Administration (DEA) is correcting a final rule that appeared in the Federal Register of November 12, 2015 (80 FR 69861). The document issued an action placing the substance 5- [[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1- oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]meth yl]-2- methoxybenzoic acid (eluxadoline), including its salts, isomers, and salts of isomers, into schedule IV of the Controlled Substances Act. This document inadvertently included a paragraph in the regulatory text that was not intended for publication, and was unable to be removed before being placed on public inspection. This document corrects the final rule by removing this paragraph.
Manufacturer of Controlled Substances Registration: Austin Pharma LLC
Austin Pharma LLC applied to be registered as a manufacturer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Austin Pharma LLC registration as a manufacturer of those controlled substances.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.